News & Events

Tryton Medical Announces CE Mark and European Launch of Next-Generation Tryton Side Branch SHORT Stent

New Stent Will Be Featured at EuroPCR 2013 Exhibit Booth #M27 May 21-24 in Paris Durham, N.C. – May 16, 2013 – Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced that the company received the CE Mark for the Tryton Side Branch SHORT Stent, a novel coronary stent system that broadens the treatment options in bifurcations in large vessels with a short main branch landing zone. The Tryton Side Branch SHORT Stent length is 15 mm, or 3mm shorter in the main branch zone than the standard...

read more

RiverVest Venture Partners Names Pharmaceutical Veteran Bradley Keller as Entrepreneur-in-Residence

ST. LOUIS (May 13, 2013) – RiverVest Venture Partners announced today that Bradley Keller, Ph.D. has joined the life sciences venture capital firm as an Entrepreneur-in-Residence. Keller brings with him more than 20 years of experience in drug discovery and development, including scientific leadership roles at Pfizer, Pharmacia, Monsanto/Searle and Hoffman-LaRoche, and most recently, as Global Product Manager with Sigma-Aldrich. As a 2009-10 Innovation Acceleration Partnership Fellow at Washington University in St. Louis, Keller participated...

read more

Lumena Pharmaceuticals Announces $23 Million Series A Financing

 Funding to support clinical development of drug candidates to treat rare liver diseases  SAN DIEGO – May 8, 2013 – Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the company has secured $23 million in Series A financing. Investors include Pappas Ventures, RiverVest Venture Partners and Alta Partners. Founded in 2011 by Pappas Ventures, Lumena will primarily use the funding to advance the clinical development of LUM001, the company’s lead product candidate for the treatment of...

read more

St. Mary Medical Center and Centerre Healthcare Partner in Opening New Inpatient Rehabilitation Specialty Hospital

State-of-the-art facility to be first free-standing rehabilitation hospital in Bucks County LANGHORNE, PA, April 29, 2013 – St. Mary Medical Center in Langhorne, PA, in partnership with Centerre Healthcare Corporation, headquartered in Nashville, TN, today announced plans for a newly designed acute rehabilitation hospital, the first specialty hospital of its kind in Bucks County. Scheduled for completion in the spring of 2014, the St. Mary Rehabilitation Hospital will provide acute inpatient rehabilitation services for patients who require a...

read more

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

New claim will help physicians better guide treatment with P2Y12 Inhibitors April 16, 2013, San Diego, CA – Accumetrics, Inc., developer of the market-leading VerifyNow® System, announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to assess whether a patient may be at greater risk for both bleeding or ischemic events, as an aid to manage therapeutic treatment decisions and accurately assess the antiplatelet effect from P2Y12 inhibitors (such as clopidogrel, prasugrel and...

read more

Mercy Breaks Ground on New Rehabilitation Hospital

Springfield, MO. (April 2, 2013) — Rehabilitation services in the Ozarks will get a major upgrade, as crews begin work on the new Mercy Rehabilitation Hospital Springfield. The $28 million, 63,000 square foot facility will have 60 beds and provide inpatient rehabilitation for patients who are recovering from strokes, brain or spinal cord injuries, amputations, complex orthopedic injuries and other conditions. Construction is estimated to take about a year. Currently, rehabilitation services are offered at Mercy Hospital Springfield. As a...

read more

RiverVest Venture Partners’ O’Donnell Named to Experts Advisory Panel at Stevenage Bioscience Catalyst

ST. LOUIS (March 26, 2013) – RiverVest Venture Partners’ Principal Niall O’Donnell, Ph.D., has been invited to serve on the Experts Panel at Stevenage Bioscience Catalyst, the U.K.’s first open innovation bioscience campus focused on driving early-stage biotech, pharma and medtech developments. O’Donnell joins a panel of commercial, financial and technical experts advising Bioscience Catalyst and its tenants on all aspects of business development. Funded by partners including GlaxoSmithKline and the Wellcome Trust and located just...

read more

Rady Venture Fund Develops Next Generation Tech Investors

SAN DIEGO, March 20, 2013 /PRNewswire-USNewswire/ — The Rady School of Management’s student-run venture capital fund, the Rady Venture Fund, has participated in a $16 million Series B raise in startup Savara Pharmaceuticals, which is developing an inhalable antibiotic to treat cystic fibrosis patients with lung infections. The Rady Venture Fund’s investment in Savara was made in conjunction with an investment by the Tech Coast Angels, the largest and most active angel investor network in the U.S. The investment provided Rady...

read more

RiverVest Venture Partners’ Returns More than Double Other Top Healthcare Venture Funds

ST. LOUIS (March 12, 2013) – RiverVest Venture Partners announced today that its Fund II has delivered a return of more than double that of a respected benchmark that delineates top-performing venture capital funds. Focusing exclusively on life science innovations, RiverVest delivered to its Fund II limited partners a 14.5% per annum net internal rate of return (IRR) from inception in 2006 through the end of last year, after fees and expenses. The median net IRR for all reporting VC funds begun the same year, including IT funds, was 4.54%,...

read more

Clinical Utility of Platelet Reactivity Strongly Advocated at ACC.13

New Studies Demonstrate Cost Effectiveness, Clinical Value in a Stent Population and Validation of a Therapeutic Window using the VerifyNow System March 12, 2013, San Diego, CA – Accumetrics, Inc., developer of the market-leading VerifyNow® System, announced the presentation of a series of important data that solidifies the clinical utility of platelet reactivity testing. Real world outcomes data in high risk patients receiving stents, a cost effectiveness analysis, and validation of a therapeutic window continue to demonstrate platelet...

read more